CNTO 3157

Drug Profile

CNTO 3157

Alternative Names: CNTO-3157; JNJ-42915925; PRV-300

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Centocor Ortho Biotech; MorphoSys
  • Developer Janssen Biotech
  • Class Antiasthmatics; Bronchodilators; Monoclonal antibodies
  • Mechanism of Action Toll-like receptor 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma

Most Recent Events

  • 21 Sep 2017 CNTO 3157 licensed to Provention Bio
  • 21 Sep 2017 Provention Bio plans a phase I/II trial for Ulcerative colitis in first half of 2018
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Asthma in Belgium (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top